The FDA is giving a thumbs-up to the first human trial involving embryonic stem cells. The study, which will examine the safety of this treatment in people with spinal cord injuries, comes in advance of a widely-anticipated shift in U.S. policy on embryonic stem cells. Join Kojo as we explore the intersection of bioethics and stem cell research.

Guests

  • Alicia Mundy Reporter, The Wall Street Journal
  • Ruth Faden Philip Franklin Wagley Professor of Biomedical Ethics and Director, Berman Institute of Bioethics, Johns Hopkins University
  • Richard Garr Chief Executive Officer, Neuralstem, Inc.

Topics + Tags

Most Recent Shows